Recent News on

Luncheon with the Experts in New York City

April 13, 2014

Join carcinoid and neuroendocrine tumor patients on Sunday, May 4, 2014 for a unique opportunity to have lunch with three medical experts.  Share your experiences with others who have similar concerns and hear from the physicians on issues ranging from NET cancer treatments and surgery to carcinoid heart disease to follow-up testing and new developments.  Read more

AJCC Names Chair of Neuroendocrine Tumors Expert Panel

April 7, 2014

Eugene A. Woltering, MD, The James D. Rives Professor of Surgery and Neuroscience and Director of Surgical Research at LSU Health Sciences Center in Kenner, Louisiana, has been selected to serve as Chair of the Neuroendocrine Tumors Expert Panel for the American Joint Committee on Cancer’s (AJCC) Cancer Staging System, 8th Edition. Read more

Now Online -- New Jersey Carcinoid Cancer NETwork Conference Videos

January 20, 2014

Videos from the New Jersey Carcinoid Cancer NETwork Conference, held on November 2, 2013, are now available online.  The guest speakers for the conference were carcinoid/neuroendocrine tumor specialists Dr. Richard R.P. Warner, Dr. Eric H. Liu, and Dr. Yi-Zarn Wang and endocrinologist Dr. Justina DeitzClick here to read more and see the videos.

Annual Appeal 2013

December 3, 2013

Please read our Annual Appeal letter from Jeffrey M. Gregory as he talks about how the Carcinoid Cancer Foundation made a significant difference for him and his wife, Jackie.  Read more about Jackie’s Journey with carcinoid.  Donations to the Annual Appeal can be made online or by mail.

You can make a real difference in the lives of those facing carcinoid cancer and other neuroendocrine tumors by supporting The Carcinoid Cancer Foundation (CCF). Your contributions help fund our work of increasing awareness and educating the general public and healthcare professionals about carcinoid and related neuroendocrine cancers; providing support for patients and their loved ones; and serving as advocates for the carcinoid/NET (neuroendocrine tumor community).  These programs lead towards our ultimate goals of early detection, a possible cure, and improving the quality of life for cancer survivors and their families.

Every donation counts -- help bring us one step closer to our goals.

Endurance Competitive Rider and Goblet Cell Carcinoid Cancer Survivor Takes on New International Challenge

November 26, 2013

Battling goblet cell carcinoid cancer has not deterred Monica Grundmann from pursuing her dream as an endurance rider with her Morab stallion, Excalibur Legend.  Next month Monica will represent Eastern Canada in the North American Team Challenge 160-km, a 24-hour Endurance Race in Florida, competing against Western Canada, the U.S. and Mexico. ““I have always and will continue to live each day as if it is my last - saying and doing the maximum,” says Monica. “Obviously my personal goals regarding my beloved stallion, his competitions and his legacy, are paramount for me. Together, he and I have achieved much more than I ever could have dreamed and I am extremely grateful for being blessed to have him.” Read more about Monica’s amazing accomplishments and her journey with a rare cancer.

FDA Grants Orphan Drug Designation to Gallium-68 DOTATOC for Neuroendocrine Tumor Management

November 22, 2013

BREAKING NEWS – The radiopharmaceutical Gallium-68 (DOTA0-hel-Tyr3) octreotide (Ga-68 DOTATOC) has been designated as an orphan drug by the US Food and Drug Administration (FDA) for the management of neuroendocrine tumors. This designation is significant because it may lead to faster approval of the agent, which would greatly benefit carcinoid/NET patients in the United States. Read more from the Society of Nuclear Medicine and Molecular Imaging and from Josh Mailman, chairman of the Society’s Patient Advocacy Advisory Board and president of the NorCal CarciNET support group in California. From the FDA, here’s information about how drugs are designated as an orphan product, read more.

Dr. M. Sue O'Dorisio Receives $100,000 Grant for Neuroendocrine Tumor Research

November 22, 2013

Sue O'Dorisio, MD

Congratulations to carcinoid/neuroendocrine tumor specialist Dr. M. Sue O’Dorisio of the University of Iowa who is one of five researchers across the country selected to receive a $100,000 “springboard grant to jumpstart a promising investigation.” The grants were given by Alex’s Lemonade Stand Foundation, a nonprofit dedicated to cancer research. Each of the projects chosen has “high impact potential for childhood cancer research.” Dr. O’Dorisio’s research will focus on neuroendocrine tumors which “constitute an unrecognized health threat to children and young adults” and could lead to the development of new treatment options. Read more

Name Your NET Hero for NET Cancer Day 2013

November 7, 2013

Name Your NET Hero to mark Worldwide NET Cancer Awareness Day, November 10th. Send in a photo of your NET Hero, and a line or two describing why he or she is your hero. Be it your doctor, nurse, spouse, friend, partner, colleague, etc., or all of them, bring these people to the spotlight, make their names and faces recognized on a global scale! Read More

NET Cancer Day 2013 Webinar

November 7, 2013

In recognition of Worldwide NET Cancer Awareness Day on November 10, NorCal CarciNet is hosting a one-hour, free webinar. Here’s a great opportunity to hear from 3 of the leading specialists in carcinoid/NET cancer treatment on NET CANCER DAY: Professor Dr. Richard P. Baum, Bad Berka, Germany; Dr. Eric Liu, Vanderbilt University, Tennessee; and Dr. Thomas O’Dorisio, University of Iowa. Read More

Coming Soon -- New Feature on Find a Doctor List

August 15, 2013

The Carcinoid Cancer Foundation welcomes feedback from the carcinoid/NET community so that we can regularly update our website, providing the most sought-after and up-to-date information possible.  Recently we were asked to add a feature to our Find a Doctor list, identifying which physicians take Medicare, Medicaid, and insurance.  We have contacted all the doctors in the United States on our current list and are presently collecting this information and preparing it as a new component on the Find a Doctor list.